Pretargeting: Taking an alternate route for localizing radionuclides

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 591-600

  Sharkey, Robert M ^a   Chang, Chien Hsing ^b   Rossi, Edmund A ^b   McBride, William J ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

Author keywords

Bispecific antibody; Cancer detection; Cancer therapy; Pretargeting; Radioimmunodetection; Radioimmunotherapy

Indexed keywords

BIOTIN I 131; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; DRUG CARRIER; FLUORODEOXYGLUCOSE F 18; HAPTEN; IMMUNOGLOBULIN G; INDIUM 111; IODINE 131; LUTETIUM 177; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90; ANTIBODY CONJUGATE; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER DIAGNOSIS; CANCER THERAPY; COLORECTAL CANCER; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG TARGETING; HUMAN; LUNG SMALL CELL CANCER; PERMEABILITY BARRIER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION; ANIMAL; NEOPLASM; RADIOIMMUNOASSAY; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; RADIOIMMUNODETECTION; RADIOISOTOPES;

EID: 84863567650     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0367-6     Document Type: Review

References (60)

1. Belda-Iniesta C, Ibanez de Caceres I, de Castro J. Monoclonal antibodies for medical oncology: a few critical perspectives. Clin Transl Oncol. 2011;13:84-7.
2. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767-74.
3. Reichert JM. Metrics for antibody therapeutics development. mAbs. 2010;2:695-700.
4. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226-43.
5. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349-70.
6. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, Azria D. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720-34.
7. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM. Antibodies against metal chelates. Nature. 1985;316:265-8.
8. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttriumand iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990;50:2330-6.
9. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of geneticallyengineered antibodies. Q J Nucl Med. 1998;42:225-41.
10. Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, Frincke JM. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650-5.
11. Stickney DR, Slater JB, Kirk GA, Anderson LD, Chang C-H, Frincke JM. Bifunctional antibody: ZCE/CHA 111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconjug Radiopharm. 1989;2:1-13.
12. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-66.
13. Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, Barbet J. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer. 1997;80:2618-23.
14. Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med. 1998;39:1937-43.
15. 131I-labeled bivalent hapten. J Nucl Med. 2000;41:480-7.
16. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-302.
17. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155-9.
18. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-34.
19. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother. 1994;16:158.
20. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802-7.
21. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardies M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Pharmacokinetics and dosimetry studies for optimization of anticarcinoembryonic antigen × anti-hapten bispecific antibodymediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973S-81.
22. 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-55.
23. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonicantigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-11.
24. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-88.
25. De Nardo SJ, De Nardo GL, Brush J, Carter P. Phage libraryderived human anti-TETA and anti-DOTA scFv for pretargeting RIT. Hybridoma. 1999;18:13-21.
26. Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imag Biol. 2011;13:215-21.
27. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol. 1990;27:995-1000.
28. Morel A, Darmon M, Delaage M. An immunoenzymoassay for histamine. Agents Actions. 1990;30:291-3.
29. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, Cohen M, Milhaud G, Tartar A, Rostene W, Barbet J, Gruaz-Guyon A. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem. 1997;8:526-33.
30. Hosono M, Hosono MN, Kraeber-Bodere F, Devys A, Thedrez P, Faivre-Chauvet A, Gautherot E, Barbet J, Chatal JF. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med. 1999;40:1216-21.
31. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354-63.
32. 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678-88.
33. 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med. 2004;45:30-9.
34. 68Ga. J Nucl Med. 2011;52:555-9.
35. 18F radiolabeling for PET. J Nucl Med. 2009;50:991-8.
36. 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21:1331-40.
37. 18F chelation. Bioconjug Chem. 2011;22:1793-803.
38. Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBride W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, Goldenberg DM. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res. 2005;11:7122s-9.
39. Rossi EA, Sharkey RM, McBride W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH. Development of new multivalentbispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res. 2003;9:3886S-96.
40. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103:6841-6.
41. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158-63.
42. Rossi EA, Goldenberg DM, Chang CH: The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2011; doi: 10.1021/bc2004999PMID: 22168444.
43. Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem. 2002;13:1054-70.
44. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250-5.
45. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11:7109s-21.
46. Sharkey RM, Karacay H, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin Cancer Res. 2007;13:5577s-85.
47. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282-90.
48. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ, Goldenberg DM. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 2008;246:497-507.
49. Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009;50:444-53.
50. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190-203.
51. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11:7879-85.
52. 111In-labeled hapten-peptide (IMP 288) in ovarian cancer. J Nucl Med 2010;51:Abst 1148.
53. 90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med. 2009;50:2008-16.
54. 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019-27.
55. Frampas E, Maurel C, Remaud-Le Saec P, Mauxion T, Faivre-Chauvet A, Davodeau F, Goldenberg DM, Bardies M, Barbet J. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging. 2011;38:2153-64.
56. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros G. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113-47.
57. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm. 2010;25:581-8.
58. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med. 2008;49:1884-99.
59. Schoffelen R, Boerman OC, van der Graff WT, van Herpen CM, Sharkey RM, McBride WJ, Chang CH, Rossi EA, Goldenberg DM, Oyen WJ. Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): first results. J Nucl Med. 2011;52:107 (abstr 358).
60. Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, Rossi EA, Eek A, Oyen WJ, Boerman OC. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780-7.